JP4758063B2 - 癒着、関節炎及び乾癬の治療へのフカン類の使用 - Google Patents

癒着、関節炎及び乾癬の治療へのフカン類の使用 Download PDF

Info

Publication number: JP4758063B2
Authority: JP; Japan
Prior art keywords: fucan; use according; fucoidan; pharmaceutical composition; administration
Prior art date: 2001-08-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2003522551A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005508893A (ja

JP2005508893A5 (fr

Inventor

ジャクソン、ジョン、ケィ．

バート、ヘレン、エム．

Original Assignee

ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-29

Filing date

2002-08-29

Publication date

2011-08-24

2002-08-29 Application filed by ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア filed Critical ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア

2005-04-07 Publication of JP2005508893A publication Critical patent/JP2005508893A/ja

2006-01-05 Publication of JP2005508893A5 publication Critical patent/JP2005508893A5/ja

2011-08-24 Application granted granted Critical

2011-08-24 Publication of JP4758063B2 publication Critical patent/JP4758063B2/ja

2022-08-29 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims description 18
206010003246 arthritis Diseases 0.000 title abstract description 26
201000004681 Psoriasis Diseases 0.000 title abstract description 21
229920000855 Fucoidan Polymers 0.000 claims abstract description 71
239000000203 mixture Substances 0.000 claims abstract description 21
239000003814 drug Substances 0.000 claims description 39
239000002552 dosage form Substances 0.000 claims description 27
201000010099 disease Diseases 0.000 claims description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
229940079593 drug Drugs 0.000 claims description 25
239000000546 pharmaceutical excipient Substances 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 17
239000006072 paste Substances 0.000 claims description 13
238000001356 surgical procedure Methods 0.000 claims description 12
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
239000000499 gel Substances 0.000 claims description 11
229940124597 therapeutic agent Drugs 0.000 claims description 11
229920002674 hyaluronan Polymers 0.000 claims description 10
229960003160 hyaluronic acid Drugs 0.000 claims description 10
239000007943 implant Substances 0.000 claims description 10
-1 plumbazine Chemical compound 0.000 claims description 10
238000013268 sustained release Methods 0.000 claims description 10
239000012730 sustained-release form Substances 0.000 claims description 10
208000024891 symptom Diseases 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 9
229920000642 polymer Polymers 0.000 claims description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
229920001661 Chitosan Polymers 0.000 claims description 7
108091034117 Oligonucleotide Proteins 0.000 claims description 7
239000007921 spray Substances 0.000 claims description 7
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 6
108090000994 Catalytic RNA Proteins 0.000 claims description 6
102000053642 Catalytic RNA Human genes 0.000 claims description 6
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 6
QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 claims description 6
238000007912 intraperitoneal administration Methods 0.000 claims description 6
KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 claims description 6
229960000485 methotrexate Drugs 0.000 claims description 6
239000004005 microsphere Substances 0.000 claims description 6
229920001983 poloxamer Polymers 0.000 claims description 6
229920001223 polyethylene glycol Polymers 0.000 claims description 6
108091092562 ribozyme Proteins 0.000 claims description 6
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
108010036949 Cyclosporine Proteins 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 5
229930012538 Paclitaxel Natural products 0.000 claims description 5
229940072056 alginate Drugs 0.000 claims description 5
229920000615 alginic acid Polymers 0.000 claims description 5
235000010443 alginic acid Nutrition 0.000 claims description 5
239000000074 antisense oligonucleotide Substances 0.000 claims description 5
238000012230 antisense oligonucleotides Methods 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 5
229960001265 ciclosporin Drugs 0.000 claims description 5
229930182912 cyclosporin Natural products 0.000 claims description 5
239000003112 inhibitor Substances 0.000 claims description 5
238000007918 intramuscular administration Methods 0.000 claims description 5
229960001592 paclitaxel Drugs 0.000 claims description 5
238000007920 subcutaneous administration Methods 0.000 claims description 5
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 4
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 4
229940048053 acrylate Drugs 0.000 claims description 4
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
229940127093 camptothecin Drugs 0.000 claims description 4
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 4
229960004679 doxorubicin Drugs 0.000 claims description 4
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
229960005420 etoposide Drugs 0.000 claims description 4
150000003431 steroids Chemical class 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 claims description 3
229960001338 colchicine Drugs 0.000 claims description 3
239000006071 cream Substances 0.000 claims description 3
229960003668 docetaxel Drugs 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
229960001156 mitoxantrone Drugs 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
229960002930 sirolimus Drugs 0.000 claims description 3
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
229960001940 sulfasalazine Drugs 0.000 claims description 3
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
235000012711 vitamin K3 Nutrition 0.000 claims description 3
239000011652 vitamin K3 Substances 0.000 claims description 3
229940041603 vitamin k 3 Drugs 0.000 claims description 3
239000000872 buffer Substances 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
229960000502 poloxamer Drugs 0.000 claims 2
150000004492 retinoid derivatives Chemical class 0.000 claims 1
238000000034 method Methods 0.000 abstract description 26
208000031737 Tissue Adhesions Diseases 0.000 abstract description 20
210000004027 cell Anatomy 0.000 description 39
239000010408 film Substances 0.000 description 25
230000000694 effects Effects 0.000 description 18
210000000440 neutrophil Anatomy 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 16
230000033115 angiogenesis Effects 0.000 description 15
235000013601 eggs Nutrition 0.000 description 15
241000700159 Rattus Species 0.000 description 14
210000003711 chorioallantoic membrane Anatomy 0.000 description 13
239000012528 membrane Substances 0.000 description 11
229920001610 polycaprolactone Polymers 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
230000004913 activation Effects 0.000 description 10
210000004379 membrane Anatomy 0.000 description 10
230000014509 gene expression Effects 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
108060005980 Collagenase Proteins 0.000 description 8
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 8
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 8
108091007196 stromelysin Proteins 0.000 description 8
102000029816 Collagenase Human genes 0.000 description 7
210000004534 cecum Anatomy 0.000 description 7
229960002424 collagenase Drugs 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000008569 process Effects 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
210000002437 synoviocyte Anatomy 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
102000016611 Proteoglycans Human genes 0.000 description 6
108010067787 Proteoglycans Proteins 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
239000011521 glass Substances 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000000523 sample Substances 0.000 description 6
210000000329 smooth muscle myocyte Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000004659 sterilization and disinfection Methods 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
230000001093 anti-cancer Effects 0.000 description 5
210000001612 chondrocyte Anatomy 0.000 description 5
239000013078 crystal Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
208000014674 injury Diseases 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
239000008188 pellet Substances 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
230000008733 trauma Effects 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
108010073385 Fibrin Proteins 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
230000009471 action Effects 0.000 description 4
230000001772 anti-angiogenic effect Effects 0.000 description 4
239000003435 antirheumatic agent Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000005038 ethylene vinyl acetate Substances 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000006210 lotion Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
230000002265 prevention Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000005855 radiation Effects 0.000 description 4
210000004927 skin cell Anatomy 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
229920002385 Sodium hyaluronate Polymers 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
229940124346 antiarthritic agent Drugs 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
230000008021 deposition Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
208000003243 intestinal obstruction Diseases 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000004632 polycaprolactone Substances 0.000 description 3
230000008439 repair process Effects 0.000 description 3
210000001525 retina Anatomy 0.000 description 3
238000007790 scraping Methods 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
229940010747 sodium hyaluronate Drugs 0.000 description 3
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
KAQXCFRYVVJPEV-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole;1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 KAQXCFRYVVJPEV-UHFFFAOYSA-N 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010060932 Postoperative adhesion Diseases 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
210000003837 chick embryo Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000012634 fragment Substances 0.000 description 2
108010042430 galactose receptor Proteins 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000014508 negative regulation of coagulation Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
239000002644 phorbol ester Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
238000012385 systemic delivery Methods 0.000 description 2
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
239000010409 thin film Substances 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
238000005303 weighing Methods 0.000 description 2
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241001474374 Blennius Species 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
229920004937 Dexon® Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
229920000544 Gore-Tex Polymers 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001111421 Pannus Species 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
241000199919 Phaeophyceae Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000004847 absorption spectroscopy Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000002391 anti-complement effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
108010008730 anticomplement Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
231100000762 chronic effect Toxicity 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000005336 cracking Methods 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229940000033 dermatological agent Drugs 0.000 description 1
239000003241 dermatological agent Substances 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000003278 egg shell Anatomy 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000005188 flotation Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108010015750 fucose-binding lectin Proteins 0.000 description 1
239000003517 fume Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
230000009629 growth pathway Effects 0.000 description 1
YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
210000000994 inner shell membrane Anatomy 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000007803 itching Effects 0.000 description 1
210000005067 joint tissue Anatomy 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
238000002647 laser therapy Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
238000002386 leaching Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
231100000782 microtubule inhibitor Toxicity 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000000465 moulding Methods 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
WKOVRQFUCLHTHB-UHFFFAOYSA-N n-(ethyliminomethylideneamino)-n-methylmethanamine Chemical compound CCN=C=NN(C)C WKOVRQFUCLHTHB-UHFFFAOYSA-N 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229920006302 stretch film Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000007306 turnover Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000037314 wound repair Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2003522551A 2001-08-29 2002-08-29 癒着、関節炎及び乾癬の治療へのフカン類の使用 Expired - Lifetime JP4758063B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US31536201P	2001-08-29	2001-08-29
US60/315,362		2001-08-29
PCT/CA2002/001337 WO2003018033A1 (fr)	2001-08-29	2002-08-29	Utilisation de fucanes dans le traitement des adherences, de l'arthrite et du psoriasis

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009170270A Division JP2009280597A (ja)	2001-08-29	2009-07-21	乾癬の治療へのフカン類の使用

Publications (3)

Publication Number	Publication Date
JP2005508893A JP2005508893A (ja)	2005-04-07
JP2005508893A5 JP2005508893A5 (fr)	2006-01-05
JP4758063B2 true JP4758063B2 (ja)	2011-08-24

Family

ID=23224048

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2003522551A Expired - Lifetime JP4758063B2 (ja)	2001-08-29	2002-08-29	癒着、関節炎及び乾癬の治療へのフカン類の使用
JP2009170270A Withdrawn JP2009280597A (ja)	2001-08-29	2009-07-21	乾癬の治療へのフカン類の使用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009170270A Withdrawn JP2009280597A (ja)	2001-08-29	2009-07-21	乾癬の治療へのフカン類の使用

Country Status (15)

Country	Link
US (3)	US6812220B2 (fr)
EP (1)	EP1420801B1 (fr)
JP (2)	JP4758063B2 (fr)
KR (2)	KR100910246B1 (fr)
CN (2)	CN1319540C (fr)
AT (1)	ATE376835T1 (fr)
AU (1)	AU2002325113B2 (fr)
CA (1)	CA2458853C (fr)
DE (1)	DE60223262T2 (fr)
DK (1)	DK1420801T3 (fr)
ES (1)	ES2295386T3 (fr)
MX (1)	MXPA04001876A (fr)
NZ (2)	NZ547609A (fr)
PT (1)	PT1420801E (fr)
WO (1)	WO2003018033A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6632456B1 (en) *	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP2006511475A (ja) *	2002-09-18	2006-04-06	トラスティーズオブザユニバーシティオブペンシルベニア	脈絡膜新生血管症の抑制方法
US6982298B2 (en)	2003-01-10	2006-01-03	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7465766B2 (en)	2004-01-08	2008-12-16	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8138265B2 (en)	2003-01-10	2012-03-20	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8137688B2 (en)	2003-01-10	2012-03-20	The Cleveland Clinic Foundation	Hydroxyphenyl cross-linked macromolecular network and applications thereof
JP4768440B2 (ja) *	2003-03-06	2011-09-07	セルミドリミテッド	開腹手術後の癒着の予防剤
AU2004243513A1 (en) *	2003-05-30	2004-12-09	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
AU2004274026A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
JPWO2005089800A1 (ja) *	2004-03-17	2008-01-31	株式会社ロコモジェン	ｈｓＨＲＤ３を含む医薬組成物
CA2572804C (fr) *	2004-07-09	2013-04-02	The Cleveland Clinic Foundation	Reseau macromoleculaire reticule de hydroxyphenyle et applications associees
WO2006032143A1 (fr) *	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Compositions pharmaceutiques et methodes relatives a l'inhibition d'adherences fibreuses ou de maladies inflammatoires a l'aide de fucanes a basse teneur en sulfate
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
AU2006213588B2 (en)	2005-02-09	2011-11-17	Santen Pharmaceutical Co., Ltd.	Liquid formulations for treatment of diseases or conditions
AU2006214892B2 (en) *	2005-02-16	2013-06-27	Kt & G Co., Ltd	Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US20060210697A1 (en) *	2005-03-18	2006-09-21	Mower Thomas E	Infant formula composition
US7666448B2 (en) *	2005-03-18	2010-02-23	Sakura Properties, Llc	Skin cleansing article
US20070020358A1 (en) *	2005-03-18	2007-01-25	Mower Thomas E	Sports drink concentrate
US20060210688A1 (en) *	2005-03-18	2006-09-21	Mower Thomas E	Dehydrated sports drink powder
US20060210496A1 (en) *	2005-03-18	2006-09-21	Mower Thomas E	Compositions for skin protection from ultraviolet damage
US20060210515A1 (en) *	2005-03-18	2006-09-21	Mower Thomas E	Hair growth formula
US20060210692A1 (en) *	2005-03-18	2006-09-21	Mower Thomas E	Baby food composition
US7776365B2 (en) *	2005-03-18	2010-08-17	Sakura Properties, Llc	Article with skin protecting and moisturizing compound
US7749545B2 (en) *	2005-03-18	2010-07-06	Sakura Properties, Llc	Fucoidan compositions and methods for dietary and nutritional supplements
US20060210514A1 (en) *	2005-03-18	2006-09-21	Mower Thomas E	Skin protection and moisturizing compositions and method of making the same
DK1871353T3 (da)	2005-04-15	2011-04-04	Einstein Coll Med	Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
US20070003669A1 (en) *	2005-06-02	2007-01-04	Troy Kearl	Fucoidan delivery system
US8426381B2 (en) *	2005-09-09	2013-04-23	Lucas Meyer Cosmetics Canada Inc.	Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
CA2635797C (fr)	2006-02-09	2015-03-31	Macusight, Inc.	Formulations stables et leurs procedes de preparation et d'utilisation
FR2897538B1 (fr)	2006-02-23	2008-05-02	Univ Paris Descartes	Utilisation de fucanes a des fins de greffe, d'ingenierie et de regeneration osseuses
ES2563288T3 (es)	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP4814677B2 (ja) *	2006-03-31	2011-11-16	株式会社荏原製作所	基板保持装置および研磨装置
CA2656613A1 (fr)	2006-07-03	2008-01-10	Genmab A/S	Prevention d'une eruption cutanee sur des patients subissant une therapie anti-egfr
US8080260B2 (en)	2008-02-13	2011-12-20	The Cleveland Clinic Foundation	Molecular enhancement of extracellular matrix and methods of use
US8815953B2 (en)	2008-03-13	2014-08-26	Spectrum Pharmaceuticals, Inc.	Formulations of vitamin K analogs for topical use
US8410180B2 (en)	2008-04-30	2013-04-02	The Cleveland Clinic Foundation	Methods to treat urinary incontinence
US20120071439A1 (en)	2009-03-25	2012-03-22	Saburo Minami	Cartilage production promoter and prophylactic or therapeutic agent for diseases associated with cartilage damage
JO3676B1 (ar)	2009-07-27	2020-08-27	Arc Medical Devices Inc	مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
KR101528265B1 (ko) *	2010-04-16	2015-06-11	코웨이 주식회사	베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물
US8846620B2 (en) *	2011-07-19	2014-09-30	Baxter International Inc.	Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
CN107580497A (zh) *	2015-02-16	2018-01-12	克桑蒂亚尔	用于预防或治疗皮肤病症的组合物
JP7160683B2 (ja)	2016-04-29	2022-10-25	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	術後癒着の予防及び治療のための方法及び組成物
US12186334B2 (en)	2018-07-27	2025-01-07	ARC Medical Inc.	High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
TWI854990B (zh)	2018-07-27	2024-09-11	加拿大商Ａｒｃ醫療器材公司	用於治療纖維化黏連及其他疾病和病狀之高分子量聚海藻糖（fucan）
BR112021000625A2 (pt)	2019-03-05	2021-09-21	Arc Medical Devices Inc.	Sistemas e métodos para filtração de fluxo tangencial de composições viscosas
CN111617030B (zh) *	2020-05-22	2021-09-07	广东药科大学	壳寡糖口服液及其在制备减肥药物中的应用
WO2025166450A1 (fr) *	2024-02-05	2025-08-14	ARC Medical Inc.	Compositions, dispositifs, systèmes et procédés se rapportant à l'amélioration de la plage de mouvement dans des articulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0369A (ja) *	1989-05-29	1991-01-07	Ajinomoto Co Inc	体組織癒着防止膜
JPH04506089A (ja) *	1989-06-14	1992-10-22	フレメール−アンスティティ　フランセ　ドゥ　ルシェルシュ　プール　レックスプロアタシオン　ド　ラ　メール	褐藻植物より得られた硫酸化ポリサッカライド類、抗凝固剤、抗補体剤及びその製法
JPH07101865A (ja) *	1993-09-30	1995-04-18	Morishita Roussel Kk	腹腔内癒着防止剤
WO2000020642A1 (fr) *	1998-10-02	2000-04-13	Genzyme Corporation	Prevention d'adherences
JP2000116765A (ja) *	1998-10-15	2000-04-25	Kuraray Co Ltd	癒着防止用材料

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3971848A (en) *	1970-12-21	1976-07-27	Kimitsu Chemical Laboratory Co. Ltd.	Lubricating composition for mucosa or epidermis
JPS58147064A (ja)	1982-02-25	1983-09-01	Fuji Electric Co Ltd	トランジスタ
EP0293826A3 (fr)	1987-06-02	1989-05-10	Stichting REGA V.Z.W.	Application thérapeutique et prophylactique des polysaccharides sulfatés contre le SIDA
JPS6431707A (en)	1987-07-28	1989-02-02	Nikko Chemicals	Dermal agent for external use
JPH0714850B2 (ja)	1987-09-29	1995-02-22	喜郎板谷	化粧料
JPH01313433A (ja)	1988-06-13	1989-12-18	Nippon Koutai Kenkyusho:Kk	抗ｈｉｖ剤
US6096722A (en) *	1990-08-14	2000-08-01	Isis Pharmaceuticals Inc.	Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
US5318890A (en) *	1991-05-06	1994-06-07	The Regents Of The University Of California	Assays for inhibitors of leukocyte adhesion
US5605938A (en) *	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
JP3403496B2 (ja)	1993-09-24	2003-05-06	株式会社ヤクルト本社	抗潰瘍剤およびヘリコバクター・ピロリの定着阻害剤
FR2772618B1 (fr) *	1997-12-18	2000-02-18	Ifremer	Utilisation de fucane comme regulateur de la reconstruction des tissus conjonctifs
JP2001052309A (ja)	1999-08-06	2001-02-23	Alps Electric Co Ltd	薄膜磁気ヘッドおよびその製造方法
SE0001631D0 (sv) *	2000-05-04	2000-05-04	Sahltech Ab	New use

2002
- 2002-08-28 US US10/232,850 patent/US6812220B2/en not_active Expired - Lifetime
- 2002-08-29 DK DK02758008T patent/DK1420801T3/da active
- 2002-08-29 KR KR1020047003089A patent/KR100910246B1/ko not_active Expired - Fee Related
- 2002-08-29 WO PCT/CA2002/001337 patent/WO2003018033A1/fr active Application Filing
- 2002-08-29 EP EP02758008A patent/EP1420801B1/fr not_active Expired - Lifetime
- 2002-08-29 AU AU2002325113A patent/AU2002325113B2/en not_active Ceased
- 2002-08-29 DE DE60223262T patent/DE60223262T2/de not_active Expired - Lifetime
- 2002-08-29 JP JP2003522551A patent/JP4758063B2/ja not_active Expired - Lifetime
- 2002-08-29 CN CNB028166930A patent/CN1319540C/zh not_active Expired - Fee Related
- 2002-08-29 CA CA2458853A patent/CA2458853C/fr not_active Expired - Lifetime
- 2002-08-29 KR KR1020097002751A patent/KR20090019926A/ko not_active Ceased
- 2002-08-29 AT AT02758008T patent/ATE376835T1/de active
- 2002-08-29 ES ES02758008T patent/ES2295386T3/es not_active Expired - Lifetime
- 2002-08-29 NZ NZ547609A patent/NZ547609A/en not_active IP Right Cessation
- 2002-08-29 MX MXPA04001876A patent/MXPA04001876A/es active IP Right Grant
- 2002-08-29 PT PT02758008T patent/PT1420801E/pt unknown
- 2002-08-29 CN CNA200710096370XA patent/CN101028283A/zh active Pending
- 2002-08-29 NZ NZ532015A patent/NZ532015A/en not_active IP Right Cessation
2004
- 2004-09-13 US US10/940,413 patent/US20050074496A1/en not_active Abandoned
- 2004-10-05 US US10/958,759 patent/US7163930B2/en not_active Expired - Lifetime
2009
- 2009-07-21 JP JP2009170270A patent/JP2009280597A/ja not_active Withdrawn

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0369A (ja) *	1989-05-29	1991-01-07	Ajinomoto Co Inc	体組織癒着防止膜
JPH04506089A (ja) *	1989-06-14	1992-10-22	フレメール−アンスティティ　フランセ　ドゥ　ルシェルシュ　プール　レックスプロアタシオン　ド　ラ　メール	褐藻植物より得られた硫酸化ポリサッカライド類、抗凝固剤、抗補体剤及びその製法
JPH07101865A (ja) *	1993-09-30	1995-04-18	Morishita Roussel Kk	腹腔内癒着防止剤
WO2000020642A1 (fr) *	1998-10-02	2000-04-13	Genzyme Corporation	Prevention d'adherences
JP2002526556A (ja) *	1998-10-02	2002-08-20	ジェンザイム・コーポレーション	癒着の防止方法
JP2000116765A (ja) *	1998-10-15	2000-04-25	Kuraray Co Ltd	癒着防止用材料

Also Published As

Publication number	Publication date
ATE376835T1 (de)	2007-11-15
CA2458853A1 (fr)	2003-03-06
CN1319540C (zh)	2007-06-06
JP2009280597A (ja)	2009-12-03
JP2005508893A (ja)	2005-04-07
ES2295386T3 (es)	2008-04-16
KR20040032992A (ko)	2004-04-17
MXPA04001876A (es)	2004-06-15
KR20090019926A (ko)	2009-02-25
CN101028283A (zh)	2007-09-05
US6812220B2 (en)	2004-11-02
NZ532015A (en)	2006-12-22
NZ547609A (en)	2008-07-31
EP1420801B1 (fr)	2007-10-31
US20030064958A1 (en)	2003-04-03
DK1420801T3 (da)	2008-03-03
HK1066482A1 (en)	2005-03-24
CA2458853C (fr)	2010-10-19
US20050119216A1 (en)	2005-06-02
CN1547478A (zh)	2004-11-17
WO2003018033A1 (fr)	2003-03-06
DE60223262D1 (de)	2007-12-13
AU2002325113B2 (en)	2006-10-26
US7163930B2 (en)	2007-01-16
EP1420801A1 (fr)	2004-05-26
DE60223262T2 (de)	2008-08-14
PT1420801E (pt)	2008-01-17
US20050074496A1 (en)	2005-04-07
KR100910246B1 (ko)	2009-07-31

Publication	Publication Date	Title
JP4758063B2 (ja)	2011-08-24	癒着、関節炎及び乾癬の治療へのフカン類の使用
AU2002325113A1 (en)	2003-06-05	Use of fucans in the treatment of adhesions, arthritis and psoriasis
US20070238697A1 (en)	2007-10-11	Pharmaceutical compositions and methods relating to fucans
Kheilnezhad et al.	2021	A review: progress in preventing tissue adhesions from a biomaterial perspective
US20200338114A1 (en)	2020-10-29	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
CA2527429A1 (fr)	2004-12-09	Compositions pharmaceutiques et procedes pour inhiber les adherences fibreuses au moyen de differents agents
JP2007504273A5 (fr)	2007-07-19
AU2007200318B2 (en)	2009-06-18	Use of fucans in the treatment of adhesions, arthritis and psoriasis
EP1870105A1 (fr)	2007-12-26	Utilisation de fucanes dans le traitement de la psoriasis
HK1108566A (en)	2008-05-09	Use of fucans in the treatment of adhesions, arthritis and psoriasis
HK1066482B (en)	2007-10-12	Use of fucans in the treatment of adhesions, arthritis and psoriasis
US20140134226A1 (en)	2014-05-15	Compositions and methods for inhibiting bone growth
US20170252367A1 (en)	2017-09-07	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans

Legal Events

Date	Code	Title	Description
2005-07-01	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050630
2005-07-01	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050630
2009-01-21	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090120
2009-04-21	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090420
2009-04-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090421
2009-04-28	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090427
2009-05-08	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090507
2009-07-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090721
2009-09-30	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090929
2010-01-30	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100129
2010-05-13	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100512
2010-10-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101026
2011-01-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110114
2011-04-28	TRDD	Decision of grant or rejection written
2011-05-11	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110510
2011-06-09	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110602
2011-06-10	R150	Certificate of patent or registration of utility model	Ref document number: 4758063 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2011-06-13	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20140610 Year of fee payment: 3
2014-06-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-06-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-06-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-05-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-05-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-05-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-05-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-05-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-06-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-08-29	EXPY	Cancellation because of completion of term